AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Selecta Biosciences Inc

Healthcare US SELB


Last update at 2024-01-23T20:01:58.471697Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 34.77M -9.72100M -68.87600M -55.35000M -65.33600M
Minority interest - - - - -
Net income 35.38M -25.68700M -69.78700M -53.53600M -65.33600M
Selling general administrative 23.86M 20.94M 18.91M 16.39M 18.24M
Selling and marketing expenses - - - - -
Gross profit 110.78M 85.08M 16.60M 6.68M 0.90M
Reconciled depreciation 1.29M 1.25M 0.73M 2.03M 0.97M
Ebit 14.54M -4.59700M -56.82100M -52.45500M -65.98700M
Ebitda 16.16M -4.58200M -56.73200M -53.76100M -65.01200M
Depreciation and amortization 1.62M 0.01M 0.09M -1.30600M 0.97M
Non operating income net other 23.26M -2.28000M -10.49900M - -
Operating income 14.54M -4.59700M -56.82100M -52.45500M -65.02200M
Other operating expenses 96.24M 89.67M 73.42M 59.13M 65.92M
Interest expense 3.03M 2.84M 1.56M 1.52M 1.49M
Tax provision -0.60900M 15.97M - - -
Interest income 0.98M 2.80M 1.24M 0.83M 1.05M
Net interest income -3.03100M -2.84400M -1.55600M -1.51900M -1.49400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.60900M 15.97M 0.91M -1.81400M 1.18M
Total revenue 110.78M 85.08M 16.60M 6.68M 0.90M
Total operating expenses 96.24M 89.67M 73.42M 59.13M 65.92M
Cost of revenue - - - 42.74M 47.69M
Total other income expense net 20.23M -5.12400M -12.05500M -2.89500M 1.18M
Discontinued operations - - - - -
Net income from continuing ops 35.38M -25.68700M -68.87600M -55.35000M -65.33600M
Net income applicable to common shares 35.38M -25.68700M -68.87600M -55.35000M -65.33600M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 165.89M 159.88M 165.44M 99.57M 44.48M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.78M 6.47M 5.43M 1.77M 4.67M
Total liab 72.06M 137.36M 183.44M 91.17M 49.90M
Total stockholder equity 93.83M 22.52M -18.00600M 8.40M -5.41800M
Deferred long term liab - - 0.37M - -
Other current liab 14.08M 11.13M 8.15M 13.49M 11.70M
Common stock 0.01M 0.01M 0.01M 0.00900M 0.00300M
Capital stock 0.01M 0.01M 0.01M 0.00900M 0.00300M
Retained earnings -394.93700M -430.31600M -404.62900M -335.75300M -280.40300M
Other liab - 36.84M 67.45M 56.23M 14.76M
Good will - - - - -
Other assets 1.34M 0.16M 12.70M 1.38M 0.28M
Cash 106.44M 114.06M 138.69M 89.89M 37.40M
Cash and equivalents 106.44M 114.06M 138.69M 89.89M 37.40M
Total current liabilities 25.08M 72.25M 81.55M 34.94M 35.14M
Current deferred revenue 0.59M 53.88M 72.05M 1.67M 0.96M
Net debt -68.51300M -78.77600M -103.33700M -70.61600M -16.01800M
Short term debt 10.08M 7.01M 0.91M 19.28M 21.39M
Short long term debt 8.48M 5.96M - 18.91M 21.39M
Short long term debt total 37.92M 35.28M 35.35M 19.28M 21.39M
Other stockholder equity 493.31M 457.39M 391.18M 348.66M 279.54M
Property plant equipment 2.79M 2.14M 1.40M 1.52M 2.13M
Total current assets 148.14M 144.44M 151.34M 96.67M 42.08M
Long term investments 2.00M 2.00M - - -
Net tangible assets 93.83M 22.52M -18.00600M 8.40M -5.41800M
Short term investments 28.16M 14.00M - - 0.00000M
Net receivables 9.76M 9.91M 7.22M 5.00M -
Long term debt 17.79M 19.67M 24.79M - 0.00000M
Inventory - - - - -
Accounts payable 0.32M 0.22M 0.44M 0.50M 1.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4.55800M -4.56600M -4.56300M -4.52300M -4.55700M
Additional paid in capital - - - - -
Common stock total equity 0.01M 0.01M 0.01M 0.00900M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity -394.93700M -430.31600M -404.62900M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.34M 1.47M 1.75M 1.38M 0.28M
Deferred long term asset charges - - - - -
Non current assets total 17.75M 15.44M 14.09M 2.90M 2.41M
Capital lease obligations 11.66M 9.65M 10.55M 0.37M -
Long term debt total 17.79M 19.67M 24.79M 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -13.80100M -16.05500M -0.74100M 0.23M 25.27M
Change to liabilities 1.70M 1.44M -2.81800M -0.26300M -0.61700M
Total cashflows from investing activities -15.00200M -17.14000M -0.74100M 0.23M 25.27M
Net borrowings - - 1.04M -2.80000M -2.80000M
Total cash from financing activities 39.22M 52.90M 14.43M 105.04M 0.70M
Change to operating activities - -0.39000M -7.17900M 0.78M -0.16400M
Net income 35.38M -25.68700M -68.87600M -55.35000M -65.33600M
Change in cash -7.39800M -24.62800M 48.51M 53.87M -33.34500M
Begin period cash flow 115.44M 140.06M 91.55M 37.68M 71.03M
End period cash flow 108.04M 115.44M 140.06M 91.55M 37.68M
Total cash from operating activities -31.63100M -60.38200M 34.88M -51.43500M -59.16100M
Issuance of capital stock 38.98M 51.96M 12.38M 107.66M 0.00000M
Depreciation 1.29M 1.25M 0.73M 2.03M 0.97M
Other cashflows from investing activities -13.80100M -16.05500M 0.07M 0.28M 26.16M
Dividends paid - - -0.18400M -0.02800M -
Change to inventory - 0.21M -7.17900M 0.78M -
Change to account receivables 3.32M -2.69000M -2.22400M -5.00000M -5.00000M
Sale purchase of stock 0.19M 0.16M 0.18M 0.03M 0.20M
Other cashflows from financing activities 0.05M 0.78M 21.37M 0.18M 0.50M
Change to netincome -8.88200M 11.07M 16.89M 6.37M 5.98M
Capital expenditures 1.20M 1.08M 0.81M 0.05M 0.88M
Change receivables 3.32M -2.69000M -2.22400M - -
Cash flows other operating -64.06100M -45.82800M 91.17M - -
Exchange rate changes - -0.00300M -0.05800M - -
Cash and cash equivalents changes -7.41800M -24.62800M 48.51M - -
Change in working capital -60.37700M -48.19400M 85.00M -4.48100M -0.78100M
Stock based compensation 11.19M 7.72M 5.42M 5.16M 5.71M
Other non cash items -19.11400M 2.13M 1.75M 0.40M 0.45M
Free cash flow -32.83200M -61.46700M 34.07M -51.48200M -60.04500M


  • Previous Close -
  • Market Cap135.20M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield0.0%
  • EBITDA-46.74100M
  • Revenue TTM48.69M
  • Revenue Per Share TTM0.32
  • Gross Profit TTM 38.40M
  • Diluted EPS TTM-0.29

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Selecta Biosciences Inc
- -% - 0.0 25.45 1.54 2.36 0.74 2.01
Novo Nordisk A/S
3.64 3.01% 124.57 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
5.12 4.29% 124.40 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
7.83 1.87% 427.46 30.40 24.75 10.68 6.25 9.52 20.36
1.03 1.11% 93.74 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News


Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Selecta Biosciences Inc

65 Grove Street, Watertown, MA, United States, 02472

Key Executives

Name Title Year Born
Dr. Carsten Brunn Ph.D. CEO, Pres & Director 1971
Ms. Ann K. Donohue CPA VP of Fin. & Controller 1982
Dr. Lloyd Johnston Ph.D. Chief Operating Officer 1968
Dr. Takashi Kei Kishimoto Ph.D. Chief Scientific Officer 1960
Dr. Peter G. Traber M.D. Chief Medical Officer 1955
Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D. Co-Founder and Co-Chair of the Scientific Advisory Board NA
Mr. Blaine T. Davis Chief Financial Officer 1974
Mr. Matthew Bartholomae J.D. Gen. Counsel & Sec. NA
Ms. Kristen Baldwin Chief People Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).